Please select the option that best describes you:

How do you choose between adjuvant PCV vs temozolomide in high risk oligodendroglioma with IDH mutation and 1p/19q co deletion?   

NCCN lists PCV as category 1 (and now with analysis in Abstract 2002 from ASCO 2019 showing benefit in IDH mutated), and temozolomide as 2B, yet temozolomide is commonly used in practice.



Answer from: Medical Oncologist at Academic Institution
Comments
Radiation Oncologist at Radiant Oncology
@Sani H. Kizilbash - Thank you for this reply. Do ...
Medical Oncologist at Mayo Clinic
Not yet. Accrual is still incomplete. So, CODEL is...
Sign in or Register to read more